HistoWiz appoints Dr. Linh Hoang to its Board of Directors as CEO

– USA, NY –  HistoWiz, a leading provider of digital histopathology services to academia, biotech and pharma, today announced the appointment of Dr. Linh Hoang (MD, Ph.D.) to its Board of Directors as CEO.

“We are pleased to attract Dr. Hoang to the company as the company has nearly doubled revenue in the past year and is poised for continued growth as it furthers its leadership position in the digital pathology field,” said Joseph Siletto, Board Member from Vivo Capital. “We welcome Linh to the HistoWiz team with the confidence that he is not only an experienced operator but also a strategic thinker to navigate this exciting and rapidly evolving field.”

About Dr. Linh Hoang

Dr. Linh Hoang is joining HistoWiz from Weavr Health, where he served as CEO and Chairman of the Board of Directors. Prior to Weavr, Linh served as VP and GM of Reproductive Health Diagnostics at PerkinElmer. He has also held numerous leadership roles at Thermo Fisher Scientific, including General Manager of the clinical controls and standards business and Director for Life Technologies’ personalized medicine initiatives. He was previously a consultant at Boston Consulting Group. Linh received his medical and doctoral degrees from the University of Pennsylvania and holds a bachelor’s in biochemistry from the University of Florida.

“I am proud to join HistoWiz’s accomplished team who has developed a differentiated platform to accelerate research and discovery,” said Dr. Hoang. “I’m looking forward to continuing to work with Dr. Ke Cheng in her role as President and Board Member. I am very excited to grow HistoWiz to lead the digital transformation in research histopathology and believe HistoWiz is well-positioned to become the market leader in histopathology services worldwide.”

About HistoWiz

HistoWiz automates histopathology with rapid turnaround times for researchers in academia, biotech and pharma. The company utilizes state-of-the-art technologies to process tissue specimens and host the digitized results on a proprietary platform, PathologyMap. Researchers use this advanced, online platform to manage their histology data and to collaborate with researchers across the world. With HistoWiz’s AI and proprietary tools, PathologyMap bridges researchers to a network of top pathologists for on-demand interpretation with industry-leading turnaround times. HistoWiz aims to become the global leader in histopathology to accelerate research and discovery.

For more information: https://home.histowiz.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.